Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.55 |
| ▸ | RXRB | P28702 | 6/20 | 0.55 |
| ▸ | RXRG | P48443 | 5/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13170619 | 0.91 | RXRA (0.47) | RXRARXRBRXRGPTPN5AR | |
| SCHEMBL24211025 | 0.86 | RXRA (0.50) | RXRARXRBRXRGKIF11RAPGEF4 | |
| SCHEMBL24211077 | 0.86 | RXRA (0.50) | RXRARXRBRXRGKIF11RAPGEF4 | |
| SCHEMBL31729836 | 0.86 | KIF11 (0.48) | RXRARXRBRXRGPTPN5AR | |
| SCHEMBL24518592 | 0.84 | RXRA (0.48) | RXRARXRBRXRGKIF11RAPGEF4 | |
| SCHEMBL1044865 | 0.83 | KIF11 (0.61) | ARNPBWR1KIF11 | |
| SCHEMBL13019482 | 0.83 | KIF11 (0.61) | ARNPBWR1KIF11 | |
| SCHEMBL17110032 | 0.83 | KIF11 (0.61) | ARNPBWR1KIF11 | |
| SCHEMBL26551323 | 0.83 | RXRA (0.43) | RXRARXRBRXRGPTPN5AR | |
| SCHEMBL26375411 | 0.83 | KIF11 (0.53) | RXRARXRBRXRGKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126619-A1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A COMPOUND OF FORMULA (II), AND DISPLAY DEVICE COMPRISING THE ORGANIC ELECTROLUMINESCENT DEVICE | NOVALED GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4199131-A1 | A CE(IV) METAL COMPLEX, AN ORGANIC ELECTRONIC DEVICE COMPRISING AN ANODE LAYER, A CATHODE LAYER AND A CHARGE GENERATION LAYER, WHEREIN THE CHARGE GENERATION LAYER COMPRISES A P-TYPE CHARGE GENERATION LAYER THAT COMPRISES THE CE(IV) METAL COMPLEX AND A N-TYPE CHARGE GENERATION LAYER | Novaled GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8557145-B2 | Conductive polymer compound and organic photoelectric device including same | CHEIL INDUSTRIES, INC. (KR) | 2013-10-15 | — | — | US | disclosed |
| US-8557145-B2 | Conductive polymer compound and organic photoelectric device including same | CHEIL INDUSTRIES, INC. (KR) | 2013-10-15 | — | — | US | disclosed |
| US-8114993-B2 | Use of aryl chlorides in palladium-catalyzed C-H bond functionalization | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114993-B2 | Use of aryl chlorides in palladium-catalyzed C-H bond functionalization | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114993-B2 | Use of aryl chlorides in palladium-catalyzed C-H bond functionalization | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2012-02-14 | — | — | US | disclosed |
| WO-2009069990-A2 | CONDUCTIVE POLYMER COMPOUND AND ORGANIC PHOTOELECTRIC DEVICE INCLUDING SAME | CHEIL INDUSTRIES INC. (KR) | 2009-06-04 | — | — | WO | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| WO-2008087017-A2 | NOVEL CASCADE POLYMER COMPLEXES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THE SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | WO | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | DBH, DDT, CYCS | RXRA 2443/4885RXRB 1866/4885RXRG 2336/4885 |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | RXRA 1388/4885RXRB 1708/4885RXRG 1501/4885 |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RXRA 1476/4885RXRB 1528/4885RXRG 1861/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | RXRA 3881/4885RXRB 3913/4885RXRG 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.